MADRID, June 12, 2013 /PRNewswire/ --
On 9th - 11th September, a selection of the region's most prominent C-level executives from across the pharmaceutical industry will convene at the Sheraton Mirasierra Hotel & Spa, Madrid at GDS International's fifth European Next Generation Pharmaceutical Drug Discovery Summit.
This year NGP DD 30 has elected 30 of the most well-respected decision makers from the pharmaceutical sector to meet, network, and assess the rapidly evolving industry in a vibrant, closed door environment at the 2.5 day event.
The exclusive location, the intimate number of delegates and the outstanding content offer the executives an ideal structure for new business relationships to grow. The series of interactive workshops and moderated peer-led panel discussions give delegates the opportunity to meet with business analysts and solution providers to determine strategies and solutions for the year ahead.
Included within this year's delegation are Sibo de Jong, Vice-President Pharmaceutical R&D, Astellas; Simon Read, Vice President & Head of Global Biomedical Sciences, Andreas Schneider, VP Life Science Alliances, Roche; Michael Rotte, Biomarker Development EU Head, Novartis; Dave Gunput, Head of Translational Medicine & Exploratory Development, Mitsubishi Pharmaceutical.
The industry is facing its biggest ever challenges. With the help of all involved the summit will highlight the most relevant areas in today's market. Topics to be discussed at this year's summit include; Personalizing Medicine, Slip Streaming the R&D Process & Reducing Late Stage Attrition.
Bjorn Mellgard, Global Head of Translational Medicine Gastrointestinal, Novartis attended last year's summit, and said: 'The quality of the discussions and the quality of the attendees has been really valuable. Highly relevant topics and overall, above my expectations" he added, "it was a really worthwhile investment - it's really been good to be here".
The summit aims to provide the perfect environment for key decision makers to network and collaborate with their peers, discuss organizational strategies for the future and establish meaningful working relationships with a dynamic selection of delegates, vendors and sponsors. Offering an alternative to the traditional conference format, the summits provide true innovation and value for money.
Charlotte Wright, Summit Director at GDS International, the global business event company behind NGP DD, says, "The Industry and Academia need to work alongside each other and become more open with the sharing of information if this Industry is to move forward, which I feel is where the Next Generation Pharmaceutical Drug Development 30 (NGP DD 30) comes into play. The NGP DD 30 summit brings together 30 Senior Level executives from within the Industry to network and mind share with their peers. We offer our executives an exciting opportunity to dissect the industry, share personal experiences and come up with best practices moving forward. I for one thoroughly look forward to the discussions and seeing the outcomes at the event in September. No doubt this will once again be a fantastic event!"
For more information, please visit http://www.pharmasummiteurope.com
About GDS International
GDS International creates engagement opportunities for business, onsite and online. We bring senior executives together, face-to-face, at exclusive summits, conferences, and on virtual private roundtables to advance their business with brilliant results. We create tangible business opportunities: networking platforms that help to establish thought leaders, stay in touch with existing partners, and stay abreast of crucial market, technology and regulatory developments. We're almost 20 years old. Our headquarters are based in Bristol, UK, with subsidiaries offices in New York, Miami and Sydney.
For more information about GDS International or any of its many products please visit http://www.gdsinternational.com
SOURCE GDS International